Literature DB >> 20376442

Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Yoshiaki Murakami1, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Yoshio Yuasa, Taijiro Sueda.   

Abstract

BACKGROUND: The aim of the present study was to clarify the prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
METHODS: Medical records of 103 consecutive patients with pancreatic ductal adenocarcinoma, who underwent pancreatic resection with regional and para-aortic lymph node dissection were reviewed retrospectively. Clinicopathological factors and survival were compared between patients with and without para-aortic lymph node metastasis.
RESULTS: Tumor size (p = 0.045), extrapancreatic nerve plexus invasion (p = 0.043), UICC pT factor (p = 0.026), and surgical margin status (p = 0.002) were associated significantly with para-aortic lymph node metastasis. Postoperative adjuvant chemotherapy (p < 0.001) and absence of extrapancreatic nerve plexus invasion (p = 0.041) were associated independently with longer survival, but para-aortic lymph node metastasis (p = 0.078) was not associated significantly with survival by multivariate analysis. The 2- and 5-year survival rates and median survival time of patients with and without para-aortic lymph node metastasis were 12, 0%, 12.4 months and 49, 23%, 14.5 months, respectively, and there was a significant difference in survival between the two groups by a log-rank test (p < 0.001). Postoperative adjuvant chemotherapy significantly improved the survival of patients with para-aortic lymph node metastasis (p = 0.025).
CONCLUSIONS: The prognosis of patients with para-aortic lymph node metastasis is poor in pancreatic ductal adenocarcinoma. However, postoperative adjuvant chemotherapy may improve survival.

Entities:  

Mesh:

Year:  2010        PMID: 20376442     DOI: 10.1007/s00268-010-0577-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Pancreatic adenocarcinoma: an update.

Authors:  H P Tan; J Smith; C A Garberoglio
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

4.  Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Hiroki Ohge; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  Surgery       Date:  2006-07-27       Impact factor: 3.982

5.  Prognosis factors in carcinoma of the head of the pancreas.

Authors:  F A Wenger; F Peter; J Zieren; A Steiert; C A Jacobi; J M Müller
Journal:  Dig Surg       Date:  2000       Impact factor: 2.588

6.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

7.  Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.

Authors:  Adam C Berger; Ingrid M Meszoely; Eric A Ross; James C Watson; John P Hoffman
Journal:  Ann Surg Oncol       Date:  2004-06-14       Impact factor: 5.344

8.  Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma.

Authors:  Takanori Yoshida; Toshifumi Matsumoto; Atsushi Sasaki; Kohei Shibata; Masanori Aramaki; Seigo Kitano
Journal:  Am J Surg       Date:  2004-06       Impact factor: 2.565

9.  Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.452

10.  Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-11-17       Impact factor: 3.452

View more
  24 in total

1.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

2.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

Review 3.  Mesopancreas: A boundless structure, namely the rationale for dissection of the paraaortic area in pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Nadia Peparini
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Extended lymphadenectomy in pancreatic cancer is crucial.

Authors:  Tsutomu Fujii
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

5.  Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Hayato Sasaki; Taijiro Sueda
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

Review 6.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 7.  Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.

Authors:  Christos Agalianos; Nikolaos Gouvas; Kleo Papaparaskeva; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2016-06-03       Impact factor: 3.647

8.  Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients.

Authors:  Masayuki Sho; Yoshiaki Murakami; Fuyuhiko Motoi; Sohei Satoi; Ippei Matsumoto; Manabu Kawai; Goro Honda; Kenichiro Uemura; Hiroaki Yanagimoto; Masanao Kurata; Takumi Fukumoto; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Michiaki Unno; Hiroki Yamaue; Yoshiyuki Nakajima
Journal:  J Gastroenterol       Date:  2014-10-24       Impact factor: 7.527

9.  Inferoposterior duodenal approach for laparoscopic pancreaticoduodenectomy.

Authors:  Xiao-Ming Wang; Wei-Dong Sun; Ming-Hua Hu; Gua-Nan Wang; Ya-Qi Jiang; Xiao-San Fang; Meng Han
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

10.  N-wasp in pancreatic ductal adenocarcinoma: associations with perineural invasion and poor prognosis.

Authors:  Jun-Chao Guo; Jian Li; Yu-Pei Zhao; Li Zhou; Quan-Cai Cui; Wei-Xun Zhou; Tai-Ping Zhang; Lei You; Hong Shu
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.